This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

CTI BioPharma Balance Sheet Health

Financial Health criteria checks 0/6

CTI BioPharma has a total shareholder equity of $-25.3M and total debt of $116.5M, which brings its debt-to-equity ratio to -459.4%. Its total assets and total liabilities are $112.3M and $137.6M respectively.

Key information

-459.4%

Debt to equity ratio

US$116.46m

Debt

Interest coverage ration/a
CashUS$59.01m
Equity-US$25.35m
Total liabilitiesUS$137.62m
Total assetsUS$112.27m

Recent financial health updates

Recent updates

CTI BioPharma: Reiterating Target Price Of $17 After Successful VONJO Launch

Aug 17

CTI BioPharma GAAP EPS of -$0.21 misses by $0.01, revenue of $12.33M beats by $3.23M

Aug 08

CTI BioPharma: Approval Is Great, Now There's The Follow Through

Jul 19

CTI BioPharma initiated at outperform at Cowen on potential for Vonjo for myelofibrosis

Jul 07

CTI BioPharma - 3.2x Potential Upside On A De-Risked Asset

May 04

CTI BioPharma Corp.: Pacritinib Approval, Downgrade To A Sell Rating

Apr 11

CTI BioPharma: A Speculative Buy Into The PDUFA Date

Mar 01

CTI BioPharma: Long And Troubled History, Finally Approaching Approval

Dec 24

FDA grants 'priority review' status to CTI Biopharma's pacritinib NDA

Jun 01

CTI BioPharma initiated buy at Stifel; cites potential in myelofibrosis

May 06

CTI BioPharma: Accelerated Approval Pathway Looks Attractive

Dec 06

Financial Position Analysis

Short Term Liabilities: CTIC has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: CTIC has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: CTIC has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: CTIC's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CTIC has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CTIC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 16.9% each year


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.